A large proportion of pharmaceutical development is funded (directly or indirectly) by public funds. There's a very strong argument that single-payer healthcare systems should issue a blanket moratorium on buying new patented medicines and direct the funds to research. Major pharmaceutical companies spend significantly more on marketing than on R&D, so it'd be a net win for the taxpayer if they just paid for drug development directly.